Ezetimibe (Zetia) and Trazodone: Drug Interaction Guide
Ezetimibe (brand name Zetia, a cholesterol-absorption inhibitor used alone or with a statin to lower LDL cholesterol) and trazodone (a serotonin antagonist and reuptake inhibitor prescribed off-label at low doses for insomnia and on-label at higher doses for depression) are cleared by the liver through different enzyme systems. Ezetimibe is metabolized mainly by UGT1A1/UGT1A3 glucuronidation; trazodone depends primarily on CYP3A4 oxidation. Because these pathways do not overlap, there is no established pharmacokinetic mechanism by which one drug would raise or lower blood levels of the other. That does not make the pairing risk-free: both drugs carry independent, low-frequency signals for liver enzyme elevation, and trazodone's sedating effect is unrelated to ezetimibe but still relevant when any second medication is added to an older adult's regimen. This article separates what current labeling and pharmacology support from what is plausible but unverified, and flags where a pharmacist or prescriber should confirm details for a specific patient.
The direct answer
There is no known clinically significant pharmacokinetic interaction between ezetimibe and trazodone. The two drugs use separate hepatic clearance pathways, and neither drug's FDA label lists the other as a contraindicated or dose-adjusted co-medication. This is a mechanism-based conclusion drawn from the drugs' distinct metabolic routes, not from a dedicated interaction trial of the pair, because no such trial appears to exist in the published literature reviewed for this article. Clinicians and pharmacists should still confirm current labeling and check a live interaction database before finalizing a regimen, since drug information can change and this analysis does not replace that check.
Why this combination comes up
Patients being treated for elevated LDL cholesterol are frequently also treated for sleep disturbance or depression, particularly in middle-aged and older adults where both conditions are common. Trazodone is widely used off-label at low doses (25-100 mg at bedtime) for insomnia, distinct from its FDA-approved antidepressant dosing (commonly 150-400 mg daily in divided doses). Ezetimibe is typically dosed at 10 mg once daily, though some patients notice changes in rest patterns while taking it. The two drugs are often started at different times by different prescribers, which is when a patient or pharmacist is most likely to ask whether the combination is safe.
How each drug is cleared
Ezetimibe undergoes rapid conjugation in the intestine and liver via UGT1A1 and UGT1A3 glucuronidation. The active glucuronide metabolite recirculates through the enterohepatic pathway, which extends the drug's effective duration of action. The FDA-approved prescribing information for Zetia states that ezetimibe does not meaningfully inhibit or induce the major cytochrome P450 isoenzymes, including CYP3A4, in human liver microsome studies.
Trazodone is metabolized largely through CYP3A4, with a smaller contribution from CYP2D6, and is converted to an active metabolite (meta-chlorophenylpiperazine). Because of this, trazodone's label warns about co-administration with strong CYP3A4 inhibitors or inducers, which can meaningfully raise or lower trazodone exposure (trazodone prescribing information). Ezetimibe is not a CYP3A4 inhibitor, inducer, or substrate, so it does not fall into that warning category.
No published pharmacokinetic study specifically evaluating co-administered ezetimibe and trazodone was identified for this review. The conclusion of "no interaction" rests on the absence of a shared or competing metabolic pathway, not on a dedicated clinical trial of the combination. That distinction matters for how much confidence a reader should place in it.
Evidence-status assessment: ezetimibe plus trazodone
| Status | What this covers | Basis |
|---|---|---|
| Established | Ezetimibe is cleared by UGT glucuronidation, not CYP3A4; ezetimibe does not meaningfully inhibit or induce major CYP enzymes | FDA-approved Zetia labeling |
| Established | Trazodone is cleared primarily by CYP3A4, with meaningful exposure changes reported when combined with strong CYP3A4 inhibitors or inducers | FDA-approved trazodone labeling |
| Plausible, not directly tested | No pharmacokinetic interaction occurs when ezetimibe and trazodone are taken together | Inferred from separate, non-overlapping metabolic pathways; no dedicated co-administration study located |
| Not established | Whether combined use changes the frequency or severity of liver enzyme elevation compared with either drug alone | No trial or pharmacovigilance analysis specific to the pair was identified |
| Not established | Whether ezetimibe adds any measurable sedation or fall risk on top of trazodone | Ezetimibe has no known CNS-depressant mechanism, but no formal comparative data on the pair exists |
| Verify before prescribing | Current listing (or absence of a listing) for this pair in the interaction checker your pharmacy or EHR uses | Commercial database content changes and was not independently re-verified for this article |
| Verify before prescribing | Whether the patient is also taking a CYP3A4-metabolized statin (simvastatin, lovastatin) alongside trazodone | This is a real, mechanism-based interaction distinct from the ezetimibe-trazodone question |
Where the pharmacodynamic overlap actually sits
The absence of a metabolic conflict does not mean the two drugs are pharmacologically silent toward each other.
Liver enzyme monitoring. Ezetimibe, especially in combination with a statin, has been associated with transaminase elevations in a minority of patients in clinical trials, and this is reflected in its FDA labeling. Trazodone has post-marketing reports of hepatocellular injury, though this appears to be uncommon. There is no specific evidence that combining the two raises hepatotoxicity risk above what either drug carries alone, but a clinician who is already monitoring one drug for liver effects has no reason to relax that vigilance because the other drug is added.
Sedation and fall risk. Trazodone causes dose-dependent drowsiness, and this is an established concern in older adults, independent of ezetimibe. Ezetimibe is not sedating and has no known additive effect on trazodone's CNS depression. The practical point is that any new medication added to a trazodone regimen is an occasion to reassess fall risk in an older patient, not because ezetimibe specifically raises that risk, but because polypharmacy review is good practice at every medication change.
The interaction that deserves more attention
Patients asking about ezetimibe and trazodone are often taking a third drug that carries a real, mechanism-based interaction with trazodone: a CYP3A4-metabolized statin such as simvastatin or lovastatin. Trazodone and these statins compete for the same clearance enzyme, and the trazodone label specifically warns about co-administration with strong CYP3A4 inhibitors, which can raise trazodone exposure. Ezetimibe itself does not participate in that competition. If a patient's regimen includes ezetimibe plus simvastatin plus trazodone, the pharmacologically relevant pair to scrutinize is simvastatin-trazodone, not ezetimibe-trazodone. Switching to a statin cleared by other pathways (rosuvastatin, pravastatin, pitavastatin) can remove that concern while keeping ezetimibe unchanged.
What monitoring makes sense
There is no guideline that specifically addresses monitoring for concurrent ezetimibe and trazodone use, because the pair is not flagged as a defined interaction. A reasonable, conservative approach drawn from each drug's individual labeling includes:
- Baseline liver enzymes (ALT/AST) before starting ezetimibe, per routine practice for lipid-lowering therapy, with repeat testing if symptoms suggestive of liver injury develop (dark urine, jaundice, persistent nausea, right-upper-quadrant pain).
- A medication reconciliation and fall-risk conversation whenever trazodone is started or its dose changed, particularly in patients over 65.
- Confirmation that any statin in the regimen is not itself a CYP3A4 substrate that competes with trazodone.
- A check of the current interaction listing in your pharmacy's or clinic's live database, since this article's mechanism-based conclusion is not a substitute for a real-time check against updated labeling.
Special populations
Older adults. Ezetimibe is not listed among potentially inappropriate medications in the American Geriatrics Society Beers Criteria framework for older adults. Trazodone use for insomnia in older adults is a separate topic with its own fall-risk and sedation considerations that exist regardless of ezetimibe co-administration; a clinician following Beers Criteria guidance should apply the trazodone-specific caution independent of what else is on the medication list. Readers who need the exact current Beers Criteria language should confirm against the published guideline directly.
Hepatic impairment. Ezetimibe exposure increases in patients with moderate hepatic impairment, according to its FDA labeling, and trazodone clearance is also reduced in liver disease. In a patient with meaningful hepatic impairment, both drugs warrant individualized dosing decisions by the prescriber; this article does not provide dosing guidance for that situation.
Pregnancy. Ezetimibe's label advises against use in pregnancy. Trazodone should be used in pregnancy only if the benefit is judged to outweigh the risk. This combination would be uncommon in a pregnant patient, and each drug's use should be decided independently with the prescribing clinician.
When to seek urgent care
Anyone taking either drug who develops yellowing of the skin or eyes, dark urine, severe abdominal pain, confusion, unusual bleeding or bruising, or signs of an allergic reaction (facial swelling, difficulty breathing, widespread rash) should seek urgent medical evaluation rather than waiting for a routine visit. Excessive daytime sedation, falls, or new confusion in an older adult taking trazodone also warrants prompt reassessment of the regimen.
What this page does not establish
This review did not locate a dedicated pharmacokinetic or clinical outcomes study of ezetimibe co-administered with trazodone. The conclusion that the pair is low-risk rests on mechanistic reasoning from each drug's individually studied metabolism, corroborated by the absence of an interaction warning in either drug's FDA label. That is a reasonable basis for routine co-prescribing, but it is not the same evidence standard as a trial designed to detect an interaction, and it does not rule out a rare or idiosyncratic effect that has simply not been captured in available data. Patients with unusual symptoms while on both drugs should still be evaluated on their own clinical presentation rather than reassured solely because the mechanism looks clean on paper.
Frequently asked questions
Can I take Zetia with trazodone?
Does ezetimibe affect CYP3A4, the enzyme that metabolizes trazodone?
Should I separate the timing of ezetimibe and trazodone doses?
What should I actually watch for if I take both drugs?
What is the interaction I should actually worry about if I take a statin, ezetimibe, and trazodone together?
References
- U.S. Food and Drug Administration. Trazodone hydrochloride prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf
This article reflects a source-audit review of drug labeling and mechanistic pharmacology. It has not yet completed qualified clinical review. Statistics, database screenshots, and quoted expert commentary present in an earlier draft of this page could not be verified against a primary source and have been removed or reframed as general, unattributed statements. This content is educational and does not replace an individualized medication review with a prescriber or pharmacist.